Innovative__O research__O described__O in__O this__O Case__B-ORG Study__I-ORG has__O led__O to__O generation__O of__O a__O strong__O portfolio__O of__O IP__O including__O the__O granting__O of__O 12__O patents__O since__O 2008,__O which__O themselves__O demonstrate__O that__O our__O scientific__O discoveries__O have__O hit__O the__O impact__O target__O of__O fulfilling__O the__O minimum__O legislative__O criteria__O of__O being__O non-__O obvious,__O novel__O and__O capable__O of__O being__O applied__O in__O trade/industry.__O
Outcomes__O of__O our__O scientific__O discoveries__O also__O include__O the__O attraction__O of__O venture__O capital__O funding__O and__O other__O investment,__O formation__O of__O the__O start-up__O company__O Diabetica__B-ORG Ltd__I-ORG and__O creation__O of__O 3__O jobs__O together__O with__O substantial__O productive__O and__O on-going__O interactions__O with__O industry__O (see__B-PER Section__I-PER 5).__O
Our__O activities__O have__O influenced__O drug__O discovery__O programmes__O and__O development__O of__O clinical__O product__O pipelines__O in__O major__O pharmaceutical__O companies__O worldwide__O (see__B-ORG Section__I-ORG 5__O for__O Testimonials).__B-ORG
We__O have__O also__O undertaken__O significant__O contract__O research__O with__O [text__O removed__O for__O publication]__O on__O incretin__O mimetics__O and__O GIP__B-ORG antagonists,__O employing__O 2__O other__O post-doctoral__O scientists.__O
Our__O IP__O on__O GIP__O agonists__O was__O licensed__O by__O IUL/Diabetica__B-ORG Ltd.__I-ORG to__I-ORG Amylin__I-ORG Pharmaceuticals__I-ORG Ltd__I-ORG (now__O BMS)__B-ORG in__O March__O 2006,__O [text__O removed__O for__O publication].__O
This__O includes__O 2__O patent__O families__O covering__O GIP__B-ORG analogues__O as__O treatments__O of__O diabetes,__O obesity__O and__O related__O metabolic__O disease,__O with__O 11__O granted__O patents,__O including__O 4__O in__O USA__B-LOC and__O Canada__B-LOC since__O 2008.__O
As__O testimony__O to__O our__O impact__O in__O this__O field,__O GIP__O agonists__O are__O now__O pipeline__O products__O of__O Ipsen,__B-ORG Eli__I-ORG Lilly,__I-ORG and__O Amylin__B-LOC (now__O BMS)__B-MISC targeted__O for__O full__O clinical__O development__O as__O evidenced__O by__O their__O more__O recent__O IP__O filings.__O
Highly__O positive__O results__O of__O late__O preclinical__O work__O on__O N-__O terminally__O modified__O GIP__B-ORG agonists__O have__O been__O published__O recently__O by__O Amylin__B-ORG (BMS)__I-ORG scientists__O (Tatarkiewicz__B-MISC et__O al,__O Diabetes__B-ORG Obes__I-ORG Metab.__I-ORG
2013__O Jul__O 16,__O doi:__O 10.1111/dom.12181;__O see__O Section__B-ORG 5).__O
We__O have__O executed__O separate__O evaluation__O licenses__O for__O our__O IP__O on__O GIP__O antagonists__O for__O the__O treatment__O of__O obesity-insulin__O resistance,__O to__O [text__O removed__O for__O publication].__O
Our__O ground-breaking__O research__O has__O also__O driven__O industry__O to__O make__O their__O own__O IP__O filings__O and__O undertake__O related__O drug__O development__O on__O GIP__O receptor__O antagonists,__O including__O Ipsen,__B-MISC Amylin,__B-PER Sanofi__I-PER Aventis__I-PER and__O Zealand__B-LOC Pharma.__I-LOC
Further,__B-PER Zealand__I-PER has__O recently__O announced__O a__O partnership__O with__O Lilly__O to__O optimise__O new__O peptide__O candidates__O for__O diabetes.__O
As__O clear__O evidence__O of__O impact,__O our__O IP__B-ORG has__O been__O cited__O against__O their__O patent__O filings,__O being__O included__O in__O numerous__O International__B-ORG search__O reports__O as__O `prior__O art'.__O
Further,__O we__O have__O now__O partnered__O with__O the__O field__O leader,__O [text__O removed__O for__O publication],__O to__O develop__O receptor-specific__O peptidergic__O therapeutic__O GIP__B-ORG antagonists__O through__O a__O Research__O Collaboration__B-MISC Agreement__I-MISC executed__O on__O 21/09/12.__O
We__O were__O also__O early__O leaders__O in__O the__O development__O of__O GLP-1__B-MISC therapeutics,__O where__O our__O innovative__O approach__O and__O published__O work__O informed__O the__O field__O of__O the__O significant__O potential__O of__O the__O GLP-1__B-ORG receptor__O as__O an__O important__O drug__O target.__O
Indeed,__O GLP-1__O mimetics__O now__O represent__O a__O major__O success__O story__O in__O diabetes__O therapy.__O
Furthermore,__O our__O subsequent__O discovery__O and__O patent__O filing__O of__O stable__O GLP-1__B-ORG and__O GIP__B-ORG therapeutics__O for__O neurodegenerative__O disease__O has__O resulted__O in__O 6__O granted__O EU__B-ORG patents__O since__O 2012__O with__O a__O further__O 7__O pending__O in__O Europe,__B-ORG USA,__I-ORG Canada__I-ORG and__O Japan.__B-LOC
This__O IP__O is__O being__O further__O co-developed__O under__O a__O Research__B-ORG Collaboration__I-ORG and__O License__B-ORG agreement__O with__O [text__O removed__O for__O publication]__O executed__O on__O 8/3/12.__O
In__O addition,__O [text__O removed__O for__O publication]__O has__O also__O contributed__O [text__O removed__O for__O publication]__O awarded__O by__O Alzheimer__B-ORG Society__I-ORG for__O a__O clinical__O trial__O of__O liraglutide__O (stable__O GLP-1__B-ORG mimetic)__O in__O patients__O with__O Alzheimer's__O disease,__O which__O is__O currently__O recruiting__O for__O patients.__O
As__O a__O result__O of__O our__O research,__O other__O pharmaceutical__O companies__O with__O GLP-1__B-ORG agonists__O in__O their__O pipeline,__O [text__O removed__O for__O publication]__O are__O also__O now__O exploring__O stable__O GLP-1__B-MISC for__O treatment__O of__O neurodegenerative__O disease.__O
Inherently__O drug__O development__O is__O a__O lengthy__O and__O perilous__O process,__O with__O low__O success__O rate.__O
In__O this__O context,__O the__O achievements__O described__O above__O plus__O our__O significant__O contract__O research__O with__O industry__O on__O the__O development__O of__O GLP-1__B-ORG and__O GIP__B-ORG mimetics__O are__O significant__O indicators__O of__O impact.__O
More__O recently,__O we__O have__O focussed__O attention__O on__O preclinical__O development__O of__O stable__O CCK-8__B-MISC therapeutics__O for__O obesity__O and__O associated__O metabolic__O disease__O [6],__B-ORG with__O 7__O granted__O EU__B-ORG patents,__O plus__O 2__O further__O patents__O granted__O in__O USA__B-LOC and__O Canada__B-LOC since__O 2008.__O
Our__O data__O have__O been__O replicated__O independently__O by__O a__O commercial__O CRO__B-ORG and__O we__O have__O engaged__O with__O more__O than__O 30__O potential__O industry__O partners__O and__O executed__O 2__O contractual__O agreements__O ([text__O removed__O for__O publication])__O to__O progress__O commercial__O development.__O
A__O significant__O contribution__O to__O this__O case__O study__O stems__O from__O the__O formation__O and__O subsequent__O commercialisation__O efforts__O of__O Diabetica__B-ORG Ltd.__I-ORG which__O was__O founded__O in__O September__O 2004__O as__O University__O start-up__O Company.__B-ORG
This__O Company__O was__O registered__O in__O Northern__B-LOC Ireland__I-LOC under__O number__O NI051793,__B-MISC as__O a__O vehicle__O to__O work__O alongside__O IUL__O to__O help__O commercialise__O technology__O generated__O by__O DRG.__B-ORG
Initial__O investment__O of__O near__O &#163;1m__B-MISC was__O from__O IUL__B-ORG and__O the__O venture__O capital__O company__O Seroba__B-ORG Bioventures,__I-ORG with__O subsequent__O employment__O of__O 3__O personnel__O and__O turnover__O of__O over__O &#163;600,000__O from__O 2004__O to__O 2011.__O
Academic__O founder__O members__O of__O Diabetica__B-ORG Ltd__I-ORG (Professors__O PR__O Flatt,__O FPM__O O'Harte__O and__O NH__B-ORG McClenaghan__I-ORG (employed__O at__O Ulster__B-LOC since__O 1998))__O were__O winners__O of__O the__O prestigious__O inaugural__O Academic__B-ORG Enterprise__I-ORG Awards__I-ORG (ACES)__I-ORG Europe__I-ORG for__I-ORG Life__I-ORG Sciences__I-ORG presented__O in__O Stockholm,__B-LOC December__O 2008.__O
Diabetica__B-PER Ltd.__I-PER and__O IUL__B-ORG continue__O to__O work__O together__O in__O exploitation__O of__O research__O conducted__O and__O interactions__O with__O industry.__O
Our__O work__O in__O the__O area__O of__O novel__O peptide__O therapeutics__O for__O diabetes__O and__O interactions__O with__O industry__O has__O been__O recognised__O internationally__O also__O by__O prestigious__O personal__O awards.__O
Professor__O PR__B-PER Flatt__I-PER was__O elected__O Member__B-ORG Royal__I-ORG Irish__I-ORG Academy__I-ORG (2006)__O and__O awarded__O Dorothy__B-ORG Hodgkin__I-ORG Lecture__I-ORG of__I-ORG Diabetes__I-ORG UK__I-ORG (2007).__O
Other__O prizes__O include__O Biochemistry__B-ORG Society__I-ORG Medal__I-ORG (Professor__I-ORG PR__I-ORG Flatt,__I-ORG 2005),__O Endocrine__B-ORG Society__I-ORG Nordisk__I-ORG Medal__I-ORG (Professor__I-ORG FPM__I-ORG O'Harte,__I-ORG 2006)__O and__O European__B-ORG Association__I-ORG for__I-ORG the__I-ORG Study__I-ORG of__I-ORG Diabetes__I-ORG (EASD)__I-ORG Rising__I-ORG Star__I-ORG (Professor__I-ORG VA__I-ORG Gault,__I-ORG 2009).__O
Professor__O PR__O Flatt__O was__O also__O member__O of__O the__O influential__O international__O working__O group__O of__O Juvenile__B-ORG Diabetes__I-ORG Research__I-ORG Foundation__I-ORG Ltd__I-ORG (JDRF)__O formulating__O the__O 2013__O roadmap__O for__O the__O direction__O of__O future__O UK__B-LOC research__O funding__O in__O type__O 1__O diabetes.__O
